Special Issue

Personalized Medicine for Metabolic Diseases: Novel Tools for the Study of Pathogenic Mechanisms and Treatment

Message from the Guest Editor

Metabolic diseases are often genetic and rare, affecting less than 1/10000 individuals. However, as there are thousands of these diseases, many millions of individuals are affected. The human and social burdens are clear, and new therapeutic approaches and needed. From a biochemical, biophysical and cell biology point of view, the treatment of inherited metabolic diseases is challenging. We welcome multidisciplinary original research and review articles that address the molecular mechanisms of these diseases, as well as novel approaches to their investigation and treatment. We aim to gather papers that use classical and state-of-the-art tools to unravel different aspects of metabolic diseases (such as structure-function relationships), and welcome metabolomic and proteomic studies. We also aim to present current advances in X-ray crystallography and cryo-EM for the investigation of these diseases. We seek reviews, comments and original research. It is particularly important that manuscripts be of high quality and relevance if state-of-the-art approaches are used, described or discussed.

Guest Editor

Dr. Angel L. Pey

Department of Physical Chemistry, University of Granada, Granada, Spain

Deadline for manuscript submissions

closed (10 June 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/163037

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

